At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation : A Unicentric, Safe, and Feasible Program
Ruiz-Boy, Sonia (Hospital Clínic i Provincial de Barcelona)
Pedraza, Alexandra (Hospital Clínic i Provincial de Barcelona)
Prat, Marta (Hospital Clínic i Provincial de Barcelona)
Salas, María Queralt (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Carcelero, Ester (Hospital Clínic i Provincial de Barcelona)
Riu-Viladoms, G (Hospital Clínic i Provincial de Barcelona)
Suárez-Lledó Grande, María (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Monge-Escartín, Inés (Hospital Clínic i Provincial de Barcelona)
Rodríguez-Lobato, Luís Gerardo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Martínez-Roca, Alexandra (Hospital Clínic i Provincial de Barcelona)
Rovira Argelagués, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Martínez, Carmen (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Gallego, Cristina (Hospital Clínic i Provincial de Barcelona)
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Sánchez, Juan (Hospital Clínic i Provincial de Barcelona)
Marcos, María Ángeles (Hospital Clínic i Provincial de Barcelona)
Fernández-Avilés, Francesc (Hospital Clínic i Provincial de Barcelona)
Date: |
2023 |
Abstract: |
Cytomegalovirus (CMV) infection is a relevant cause of morbimortality in patients receiving allogeneic stem cell transplantation (allo-HCT). Foscarnet (FCN) is an effective drug against CMV administered intravenously and usually on an inpatient basis. The Home Care Unit (HCU) for hematologic patients at our hospital designed an at-home FCN administration model to avoid the hospitalization of patients requiring FCN treatment. This study analyzes whether the at-home administration of FCN is as safe and effective as its hospital administration. We collected and compared demographic, clinical, analytical, and economic data of patients with CMV infection post-allo-HCT who received FCN in the hospital (n = 16, 17 episodes) vs. at-home (n = 67, 88 episodes). The proportions of patients with cured CMV infections were comparable between the two groups (65. 9% vs. 76. 5%, p = 0. 395). The median duration of FCN treatment was 15 (interquartile range [IQR] 9-23) and 14 (IQR 11-19) days in the HCU and inpatient cohorts, respectively (p = 0. 692). There were no significant differences in the FCN toxicities between groups except for hypocalcemia (26. 1% vs. 58. 8%, p = 0. 007), which was more prevalent in the inpatient cohort. A significant cost-effectiveness was found in the HCU cohort, with a median savings per episode of EUR 5270. It may be concluded that home administration of FCN is a safe, effective, and cost-efficient therapeutic option for patients with CMV infection and disease. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Cytomegalovirus ;
Allogeneic stem cell transplantation ;
Foscarnet ;
At-home model |
Published in: |
Pharmaceuticals, Vol. 16 Núm. 12 (december 2023) , p. 1741, ISSN 1424-8247 |
DOI: 10.3390/ph16121741
PMID: 38139867
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) >
Josep Carreras Leukaemia Research Institute Articles >
Research articlesArticles >
Published articles
Record created 2024-03-07, last modified 2024-07-18